Kyverna Therapeutics, Inc. (KYTX) stock
KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.70−0.06 (-1.26%)
Close on Nov 17, 2026Market cap $290.66MP/E –Yield –
Kyverna Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Kyverna Therapeutics's enterprise value was $140.72M on Nov 11, 2026, against $164.80M a year earlier. Over the last 3 years it ranged from -$202.60M to $347.29M, with a median of $3.58M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $140.72M | -41.5% |
| 2025 | Dec 31, 2025 | $240.56M | – |
| 2024 | Dec 31, 2024 | -$160.15M | – |
See a number that looks wrong?